サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1564934

新生児スクリーニングの世界市場

Newborn Screening

出版日
ページ情報
英文 158 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
新生児スクリーニングの世界市場
出版日: 2024年10月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 158 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

新生児スクリーニングの世界市場は2030年までに19億米ドルに達する見込み

2023年に12億米ドルと推定される新生児スクリーニングの世界市場は、2030年には19億米ドルに達し、分析期間2023-2030年のCAGRは7.1%で成長すると予測されます。新生児スクリーニングレポートで分析したセグメントの1つである消耗品は、CAGR 7.5％を記録し、分析期間終了までに14億米ドルに達すると予測されています。新生児スクリーニング機器セグメントの成長率は、分析期間中CAGR 6.3％と推定されます。

米国市場は3億1,380万米ドルと推定、中国はCAGR 10.6％で成長予測

米国の新生児スクリーニング市場は、2023年に3億1,380万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億6,720万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは10.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.6%と6.4%と予測されています。欧州では、ドイツがCAGR 4.2%で成長すると予測されています。

世界の新生児スクリーニング市場- 主要動向と促進要因まとめ

新生児スクリーニングとは何か、なぜ不可欠なのか？

新生児スクリーニングは、出生直後の乳幼児に特定の遺伝性疾患、代謝疾患、発達障害を検査する重要な公衆衛生プログラムです。これらの検査は、放っておくと発達の遅れや身体障害、さらには死亡などの深刻な健康問題につながる可能性のある状態を発見するために不可欠です。新生児スクリーニングによる早期発見により、薬物療法、食生活の改善、手術などの介入が適時に行われ、長期的な合併症を予防し、子供の生活の質を向上させることができます。

新生児スクリーニングプログラムには通常、フェニルケトン尿症（PKU）、先天性甲状腺機能低下症、鎌状赤血球症、嚢胞性線維症など、様々な疾患の検査が含まれています。技術の絶え間ない進歩により、検出可能な疾患の範囲は拡大しており、新生児スクリーニングは現代のヘルスケアに欠かせないツールとなっています。新生児スクリーニングプログラムは、これらの疾患を早期に発見することで、乳幼児死亡率の低下や公衆衛生全体の向上に貢献しています。

新生児スクリーニング市場はどのように進化していますか？

新生児スクリーニング市場は、技術の進歩とスクリーニングパネルの拡大により、急速に進化しています。市場を形成する重要な動向のひとつは、タンデム質量分析（MS/MS）の利用が増加していることです。MS/MSは、1回の血液サンプルから複数の代謝異常を検出できる技術です。この技術は、より迅速かつ正確で包括的な検査を可能にし、新生児スクリーニングに革命をもたらしました。さらに、次世代シークエンシング（NGS）を含む遺伝子スクリーニング技術が新生児スクリーニングプログラムに統合され、希少疾患を含むより広範な遺伝子疾患の検出を可能にしています。

もう一つの大きな動向は、新生児スクリーニングのポイントオブケア検査（POCT）へのシフトです。POCT機器は持ち運びが可能で、ベッドサイドですぐに検査と結果が得られるため、診断された疾患の治療開始までの時間が短縮されます。デジタルヘルスケアプラットフォームの拡大も、データ収集、分析、報告プロセスを合理化し、より効率的な新生児スクリーニングワークフローを実現することで、市場の進化に一役買っています。この進化により、特にヘルスケア・インフラへのアクセスが限られている地域では、より多くの乳幼児をより迅速にスクリーニングできるようになっています。

どのような状況が新生児スクリーニングの需要を促進していますか？

フェニルケトン尿症（PKU）や先天性甲状腺機能低下症などの代謝異常は、最もよくスクリーニングされる疾患のひとつです。これらの疾患は、早期に発見されないと深刻な発達上の問題を引き起こす可能性があるが、適切な介入により、その影響を大幅に軽減することができます。嚢胞性線維症や鎌状赤血球症などの遺伝性疾患も、早期治療によって重篤な合併症を予防し、長期的な健康転帰を改善できるため、スクリーニング需要の大きな原動力となっています。

さらに、ライソゾーム貯蔵障害（LSD）は希少遺伝性疾患の一群であり、新生児スクリーニングパネルに含まれることが多くなっています。診断技術の向上により、より多くの希少疾患が発見され、患児の予後を改善する早期治療につながっています。早期の食事介入を必要とする遺伝性代謝疾患の増加も、世界中で新生児スクリーニングプログラムの需要拡大に寄与しています。

新生児スクリーニング市場の主な成長促進要因は？

新生児スクリーニング市場の成長は、早期診断と介入が必要な遺伝性疾患や代謝性疾患の有病率の増加など、いくつかの要因によって牽引されています。新生児スクリーニングプログラムの拡大に焦点を当てた政府の義務付けやイニシアチブは、ルーチン検査に含まれる疾患の増加を確実にするため、主要な促進要因となっています。特に質量分析と遺伝子配列決定における技術の進歩も、より包括的で正確なスクリーニングを可能にすることで市場の成長を後押ししています。

もう1つの重要な要因は、長期的な健康合併症の予防における早期発見の重要性に対するヘルスケアプロバイダーや保護者の意識の高まりです。特に新興国市場では、ヘルスケアのインフラが改善するにつれて、新生児スクリーニングへのアクセスが拡大し、市場成長に寄与しています。また、公的医療機関と非公開会社の協力関係が強化され、高度なスクリーニング技術の普及と患者の予後改善につながりつつあります。

調査対象企業の例（注目の11社）

  • AB Sciex LLC
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • GE Healthcare
  • Masimo Corporation
  • Medtronic PLC
  • Natus Medical, Inc.
  • PerkinElmer, Inc.
  • Trivitron Healthcare
  • Waters Corporation

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP13586

Global Newborn Screening Market to Reach US$1.9 Billion by 2030

The global market for Newborn Screening estimated at US$1.2 Billion in the year 2023, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2023-2030. Newborn Screening Consumables, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Newborn Screening Instruments segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$313.8 Million While China is Forecast to Grow at 10.6% CAGR

The Newborn Screening market in the U.S. is estimated at US$313.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$467.2 Million by the year 2030 trailing a CAGR of 10.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Newborn Screening Market - Key Trends & Drivers Summarized

What Is Newborn Screening and Why Is It Essential?

Newborn screening is a vital public health program that tests infants for certain genetic, metabolic, and developmental disorders shortly after birth. These screenings are essential for detecting conditions that, if left untreated, can lead to severe health problems, including developmental delays, physical disabilities, and even death. Early detection through newborn screening allows for timely interventions, such as medications, dietary changes, or surgeries, which can prevent long-term complications and improve the child’s quality of life.

Newborn screening programs typically include tests for a variety of conditions, such as phenylketonuria (PKU), congenital hypothyroidism, sickle cell disease, cystic fibrosis, and more. With the continuous advancement in technology, the range of detectable disorders is expanding, making newborn screening an indispensable tool in modern healthcare. By identifying these conditions early, newborn screening programs contribute to reducing infant mortality and improving overall public health outcomes.

How Is the Newborn Screening Market Evolving?

The newborn screening market is evolving rapidly, driven by technological advancements and the expansion of screening panels. One of the key trends shaping the market is the increasing use of tandem mass spectrometry (MS/MS), a technology that allows for the detection of multiple metabolic disorders from a single blood sample. This technology has revolutionized newborn screening by enabling faster, more accurate, and comprehensive testing. Additionally, genetic screening techniques, including next-generation sequencing (NGS), are being integrated into newborn screening programs, allowing for the detection of a broader range of genetic conditions, including rare diseases.

Another significant trend is the shift towards point-of-care testing (POCT) for newborn screening. POCT devices are portable and enable immediate testing and results at the bedside, reducing the time it takes to begin treatment for diagnosed conditions. The expansion of digital healthcare platforms is also playing a role in the evolution of the market by streamlining data collection, analysis, and reporting processes, leading to more efficient newborn screening workflows. This evolution is allowing more infants to be screened faster, particularly in regions where access to healthcare infrastructure may be limited.

Which Conditions Are Driving the Demand for Newborn Screening?

Several conditions are driving the demand for newborn screening, with metabolic disorders such as phenylketonuria (PKU) and congenital hypothyroidism being among the most commonly screened. These conditions can cause serious developmental issues if not detected early, but with appropriate interventions, their impacts can be significantly mitigated. Genetic disorders, such as cystic fibrosis and sickle cell disease, are also major drivers of screening demand, as early treatment can prevent severe complications and improve long-term health outcomes.

Additionally, lysosomal storage disorders (LSDs), which are a group of rare genetic conditions, are increasingly being included in newborn screening panels. As diagnostic technologies improve, more rare diseases are being detected, leading to early treatments that can improve the prognosis for affected children. The rise of inherited metabolic disorders, which require early dietary interventions, is also contributing to the growing demand for newborn screening programs across the globe.

What Are the Key Growth Drivers in the Newborn Screening Market?

The growth in the newborn screening market is driven by several factors, including the increasing prevalence of genetic and metabolic disorders, which necessitate early diagnosis and intervention. Government mandates and initiatives focused on expanding newborn screening programs are a key driver, as they ensure that a growing number of conditions are included in routine testing. Technological advancements, particularly in mass spectrometry and genetic sequencing, are also propelling market growth by enabling more comprehensive and accurate screening.

Another important factor is the rising awareness among healthcare providers and parents about the importance of early detection in preventing long-term health complications. As healthcare infrastructure improves, especially in developing regions, access to newborn screening is expanding, contributing to market growth. Additionally, collaborations between public health organizations and private companies are increasing, leading to more widespread adoption of advanced screening technologies and better patient outcomes.

Select Competitors (Total 11 Featured) -

  • AB Sciex LLC
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • GE Healthcare
  • Masimo Corporation
  • Medtronic PLC
  • Natus Medical, Inc.
  • PerkinElmer, Inc.
  • Trivitron Healthcare
  • Waters Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Newborn Screening - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Early Detection and Prevention Drives Growth in Newborn Screening Programs Globally
    • Increasing Adoption of Genetic and Metabolic Screening Expands Opportunities for Early Diagnosis of Congenital Disorders
    • Technological Advancements in Mass Spectrometry Propel Growth in Newborn Screening for Rare Metabolic Disorders
    • Growing Focus on Early Detection of Cystic Fibrosis and Sickle Cell Disease Strengthens Demand for Newborn Screening
    • Expansion of Government-Funded Newborn Screening Programs Drives Adoption in Public Health Systems Worldwide
    • Increasing Use of Tandem Mass Spectrometry (MS/MS) in Newborn Screening Expands Precision Diagnosis Capabilities
    • Rising Adoption of DNA-Based Screening Technologies for Inherited Disorders Strengthens Market for Genomic Newborn Testing
    • Growing Demand for Point-of-Care Newborn Screening Expands Access to Early Detection in Remote and Low-Income Regions
    • Emerging Focus on Screening for Lysosomal Storage Disorders Propels Innovation in Newborn Screening Assays
    • Increasing Use of Digital Data Management Systems in Newborn Screening Programs Drives Demand for Integrated Solutions
    • Rising Demand for Expanded Newborn Screening for Immunodeficiencies and Endocrine Disorders Expands Addressable Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Newborn Screening Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Newborn Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Dry Blood Spot Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Dry Blood Spot Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Dry Blood Spot Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hearing Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hearing Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hearing Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Immunoassays & Enzymatic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Immunoassays & Enzymatic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Immunoassays & Enzymatic Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Tandem Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Molecular Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Molecular Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hearing Screening Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hearing Screening Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Hearing Screening Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Pulse Oximetry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Pulse Oximetry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Pulse Oximetry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • JAPAN
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • CHINA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • EUROPE
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Newborn Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • FRANCE
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • GERMANY
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Newborn Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • INDIA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Newborn Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Newborn Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • AFRICA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030

IV. COMPETITION